Sugi Predict

Sugi Predict / Compounds / SCHEMBL23199737

SCHEMBL23199737

SCHEMBL23199737

C[N+](C)(C)CCOP(=O)(OC[C@@H](O)CO)OC[C@@H](O)CO

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.71
▸ LMNA P02545 3/20 0.36
▸ AKT1 P31749 2/20 0.36
▸ ADRA1A P35348 2/20 0.36
▸ ESR1 P03372 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ CDC25A P30304 1/20 0.36
▸ AGTR1 P30556 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ BLM P54132 2/20 0.34
▸ PRKD3 O94806 1/20 0.34
▸ PRKCG P05129 1/20 0.34
▸ PRKCB P05771 1/20 0.34
▸ PRKCA P17252 1/20 0.34
▸ PRKCH P24723 1/20 0.34
▸ PRKCI P41743 1/20 0.34
▸ PRKCE Q02156 1/20 0.34
▸ PRKCQ Q04759 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28220408 0.90 SMN1; SMN2 (0.59) SMN1; SMN2LMNAAKT1ADRA1AESR1
SCHEMBL16267507 0.89 SMN1; SMN2 (0.58) SMN1; SMN2LMNAAKT1ADRA1AESR1
SCHEMBL5019714 0.85 SMN1; SMN2 (0.69) SMN1; SMN2LMNAAKT1ADRA1AESR1
SCHEMBL101267 0.85 SMN1; SMN2 (0.69) SMN1; SMN2LMNAAKT1ADRA1AESR1
SCHEMBL27168721 0.85 SMN1; SMN2 (0.69) SMN1; SMN2LMNAAKT1ADRA1AESR1
SCHEMBL8899300 0.85 SMN1; SMN2 (0.69) SMN1; SMN2LMNAAKT1ADRA1AESR1
SCHEMBL157824 0.85 SMN1; SMN2 (0.69) SMN1; SMN2LMNAAKT1ADRA1AESR1
Glycerin SCHEMBL28844001 0.83 SMN1; SMN2 (0.68) SMN1; SMN2LMNAAKT1ADRA1AESR1
Glycerin SCHEMBL28844000 0.83 SMN1; SMN2 (0.68) SMN1; SMN2LMNAAKT1ADRA1AESR1
SCHEMBL245306 0.83 SMN1; SMN2 (1.00) SMN1; SMN2LMNAAKT1ADRA1AESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257485-A1 GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2023-08-17 — — US disclosed
US-11673974-B2 Glycophospholipid polymeric network and use thereof BAUSCH & LOMB INCORPORATED (US) 2023-06-13 — — US disclosed
EP-4136984-A1 LIPID EMULSION FOR PARENTERAL NUTRITION COMPRISING GPC Baxter International Inc (US) 2023-02-22 — — EP disclosed
US-20210322303-A1 LIPID EMULSION FOR PARENTERAL NUTRITION COMPRISING GPC BAXTER HEALTHCARE SA (CH) 2021-10-21 — — US disclosed
EP-3801060-A1 LIPID EMULSION FOR PARENTERAL NUTRITION COMPRISING GPC Baxter International Inc. (US) 2021-04-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11673974-B2 Glycophospholipid polymeric network and use thereof ALG1, CSGALNACT1, FUT5 SMN1; SMN2 4644/4885LMNA 2758/4885AKT1 4039/4885
US-20230257485-A1 GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF ALG1, CSGALNACT1, FUT6 SMN1; SMN2 4684/4885LMNA 2560/4885AKT1 3377/4885
US-20210322303-A1 LIPID EMULSION FOR PARENTERAL NUTRITION COMPRISING GPC PNLIP, PHOSPHO1, SGMS2 SMN1; SMN2 563/4885LMNA 1866/4885AKT1 2031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.